Skin Cancer Early Diagnosis and Detection Rates Increased by New App

Share this content:

the Cancer Therapy Advisor take:

Professors Jonathan Rees, Grant Chair of Dermatology, and Bob Fisher of the School of Informatics at the University of Edinburgh in Edinburgh, United Kingdom, have developed a digital application called Dermofit to help clinicians accurately identify benign and malignant skin lesions and growths earlier in their development.


Dermofit contains photos of various skin lesions that clinicians can use to diagnose their patients more effectively. When a practitioner clicks an image of a skin lesion of interest, the application shows other similar lesions to help practitioners differentiate between the various types of skin lesions.


According to Professor Rees, 30% of doctors will refer a patient to the hospital if the patient presents with signs of a skin lesion; however, the majority of those referred patients do not have a skin malignancy and are in no danger whatsoever. By using the application, resources and money could be saved.


Dermofit is now licensed to Simedics Limited, company specializing in digital products for the healthcare sector. The company plans to launch the application in the United Kingdom later this year with plan for global markets.

Smartphone Melanoma Screening Apps
Dermofit helps clinicians accurately identify benign and malignant skin lesions.

The early diagnosis and detection rates of skin cancer has been boosted by a pioneering digital application developed at the University of Edinburgh which trains the medical profession to accurately identify malignant and benign skin lesion and skin growths at an earlier stage.

The app - named Dermofit - has now been licensed to Simedics Limited, a Yorkshire-based company specialising in digital products and publishing for the healthcare and public sector services.

Dermofit is the brainchild of Professor Jonathan Rees, Grant Chair of Dermatology at the University of Edinburgh who had the initial concept to develop a digital tool to educate GPs in order to improve skin lesion diagnosis proficiency back in 2005.

READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs